Targeting the “Undruggable” Driver Protein, KRASG12D, as Potential Therapy in Prostate Cancer

Abstract

In spite of the progress made in the development of KRASG12C inhibitors, there is still continued interest to develop inhibitors of other KRAS such as KRASG12D for the treatment of diseases, including prostate cancer, colorectal cancer, and non-small-cell lung cancer. This Patent Highlight provides exemplary compounds having activity as inhibitors of G12D mutant KRAS protein.